Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levacetylleucine SCHEMBL7085506 | 1.00 | LMNA (0.47) | LMNAFOLH1ATMCA1CA2 | |
| Levacetylleucine SCHEMBL18263873 | 1.00 | LMNA (0.47) | LMNAFOLH1ATMCA1CA2 | |
| Levacetylleucine SCHEMBL7084218 | 0.85 | LMNA (0.45) | LMNAFOLH1ATMALDH1A1PDE4B | |
| Levacetylleucine SCHEMBL21229236 | 0.85 | LMNA (0.45) | LMNAFOLH1ATMALDH1A1PDE4B | |
| Acetylleucine SCHEMBL20474775 | 0.85 | LMNA (0.45) | LMNAFOLH1ATMALDH1A1PDE4B | |
| Levacetylleucine SCHEMBL302605 | 0.85 | LMNA (0.45) | LMNAFOLH1ATMALDH1A1PDE4B | |
| Levacetylleucine SCHEMBL756572 | 0.85 | LMNA (0.45) | LMNAFOLH1ATMALDH1A1PDE4B | |
| SCHEMBL2913504 | 0.83 | CA1 (0.59) | LMNACA1CA2ACHEALDH1A1 | |
| SCHEMBL905907 | 0.83 | CA1 (0.59) | LMNACA1CA2ACHEALDH1A1 | |
| SCHEMBL7084187 | 0.83 | CA1 (0.59) | LMNACA1CA2ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| EP-3373916-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | Celgene Corporation (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3188745-A1 | DOSAGE TITRATION OF APREMILAST FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION | Celgene Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2017083348-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | CELGENE CORPORATION (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3142748-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2016025686-A1 | DOSAGE TITRATION OF APREMILAST FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION | CELGENE CORPORATION (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015175773-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2935226-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2916869-A1 | METHODS FOR THE TREATMENT OF BONE LOSS | Celgene Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2501382-A1 | APREMILAST FOR THE TREATMENT OF SARCOIDOSIS | Celgene Corporation (US) | 2012-09-26 | — | — | EP | disclosed |
| WO-2012121988-A2 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2011063102-A1 | APREMILAST FOR THE TREATMENT OF SARCOIDOSIS | CELGENE CORPORATION (US) | 2011-05-26 | — | — | WO | disclosed |
| EP-2276483-A1 | SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF | CELGENE CORPORATION (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120167-A1 | SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF | CELGENE CORPORATION (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-1965793-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079182-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |